Table 1.
Body and liver weight.
| Total mice | APFO |
|||
|---|---|---|---|---|
| n | 0mg/kg (n) | 0.1 mg/kg (n) | 0.3 mg/kg (n) | |
| Body weight (g) at start of APFO treatments | ||||
| mPPARα | 13 | 21.9 ± 0.7 (4) | 23.3 ± 2.1 (5) | 21.2 ± 1.0 (4) |
| Pparα-null | 18 | 21.5 ± 2.4 (6) | 21.4 ± 1.1 (6) | 19.4 ± 2.0 (6) |
| hPPARα | 15 | 18.4 ± 2.0 (5)$ | 20.6 ± 1.0 (5) | 19.5 ± 1.2 (5) |
| Body weight (g) after APFO treatments | ||||
| mPPARα | 13 | 24.2 ± 0.3 (4) | 24.9 ± 1.6 (5) | 23.8 ± 1.5 (4) |
| Pparα-null | 18 | 24.3 ± 1.7 (6) | 22.1 ± 0.8 (6) | 22.7 ± 1.3 (6) |
| hPPARα | 15 | 20.0 ± 2.2 (5)$ | 21.4 ± 1.4 (5) | 19.7 ± 1.9 (5) |
| Body weight change (g) | ||||
| mPPARα | 13 | 2.3 ± 0.6 (4) | 1.6 ± 0.7 (5) | 2.6 ± 2.9 (4) |
| Pparα-null | 18 | 2.8 ± 0.6 (6) | 0.7 ± 3.4 (6) | 3.2 ± 2.2 (6) |
| hPPARα | 15 | 1.6 ± 0.5 (5) | 0.8 ± 1.0 (5) | 0.1 ± 1.4 (5) |
| Liver weight (g) | ||||
| mPPARα | 13 | 1.17 ± 0.11 (4) | 1.24 ± 0.05 (5) | 1.38 ± 0.15 (4)* |
| Pparα-null | 18 | 1.24 ± 0.07 (6) | 1.05 ± 0.14 (6)* | 1.27 ± 0.15 (6) |
| hPPARα | 15 | 0.90 ± 0.14 (5)$ | 0.94 ± 0.10 (5) | 0.90 ± 0.20 (5) |
| Liver/body ratio (%) | ||||
| mPPARα | 13 | 4.85 ± 0.47 (4) | 5.02 ± 0.18 (5) | 5.78 ± 0.33 (4)* |
| Pparα-null | 18 | 5.12 ± 0.30 (6) | 4.75 ± 0.53 (6) | 5.56 ± 0.43 (6)# |
| hPPARα | 15 | 4.48 ± 0.50 (5) | 4.41 ± 0.30 (5) | 4.55 ± 0.67 (5) |
Data represent mean ± S.D.
*
Significantly different from respective control (0 mg/kg) group (P < 0.05).
#
Significantly different from respective low-dose (0.1 mg/kg) group (P < 0.05).
$
Significantly different from control of Pparα-null mice (P < 0.05).